Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Author Archives: Patrick Clinton
Preemption Watch: You've Been Warned
The Supreme Court on Wednesday issued its decision in the much-watched case of Wyeth v. Levine—which many in pharma hoped would firmly establish FDA decisions as a bulwark against common-law liability suits in state courts. The decision, as you’ve no doubt heard already, went against Wyeth. Pharm Exec’s coverage is here. The opinion is here. [...]
When the Condition You Treat is High Costs
An unmet medical need isn’t always an untreatable disease. Sometimes it’s a glitch in the healthcare system that can be made to work better by the application of just the right molecule.
That was the take-away from a conversation I had the other day with John Babich, a noted radiologist and CEO of the Cambridge, MA-based [...]
Posted in Strategy Leave a comment
Eliminate Waste (Whatever That Is)
There’s a fascinating editorial in this week’s New England Journal of Medicine by Henry J. Aaron, a healthcare economist at the Brookings Institution. Aaron argues that on average healtchare spending is not wasteful, since its benefits exceed its costs. But that doesn’t mean there isn’t waste. The trick, though, is to identify it, and as [...]
Posted in Uncategorized Tagged Brookings Institution, healthcare, Henry J. Aarons, waste Leave a comment
Now in Video, the Prix Galien Winners
At the Prix Galien awards ceremony last month, I had the opportunity to interview the winners on camera. We’ve just posted edited versions of the interviews here. Inspiring stories, remarkable people (and some great-looking tuxes). Enjoy.

Gilead Tops the BusinessWeek 50